The effects of levonorgestrel intra-uterine system on adenomyosis and endometriosis: A three year follow up study

Pramathes DasMahapatra, Partha Bhattacharyya, Pritha DasMahapatra
In: Sri Lanka Journal of Obstetrics and Gynaecology · 2012 · vol. 32(2) , pp. 27 · doi:10.4038/sljog.v32i2.3976 · W2059590084
article OA: hybrid CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This three-year follow-up study found that levonorgestrel intra-uterine systems (LNG-IUS) significantly reduced pain and bleeding in women with adenomyosis, with or without concurrent endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This three-year follow-up study evaluated the effects of a levonorgestrel intra-uterine system (LNG-IUS) on women with confirmed adenomyosis, comparing outcomes in women with adenomyosis alone versus those with co-existent endometriosis detected or excluded after laparoscopic pre-treatment. Fifty-eight participants were grouped into adenomyosis only (n=44) and adenomyosis plus endometriosis (n=14) and were assessed on five parameters including dysmenorrhea, menstrual bleeding, chronic pelvic pain, uterine volume, and endo-myometrial junctional-zone thickness. The study reported large mean reductions over three years in both groups for dysmenorrhea, menstrual bleeding, chronic pelvic pain, uterine volume, and junctional-zone thickness, with comparable effects between the groups, and noted rates such as amenorrhea (27.5%) and expulsion (6.9%). The paper explicitly concludes that LNG-IUS was equally effective for long-term conservative management of both adenomyosis alone and with endometriosis, directly addressing adenomyosis with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objective: To study effects of levonorgestrel intra-uterine system (LNG-IUS) on adenomyosis with and without endometriosis. Design: Fifty-eight women with a confirmed diagnosis of adenomyosis after exclusion of confounding factors, and detection or exclusion of endometriosis were selected. They were categorized into group A (only adenomyosis, n=44) and group B (adenomyosis plus endometriosis, pre-treated by laparoscopic surgery, n=14) received LNG-IUS between July 2004 and January 2006 and were followed up on five different parameters. Results: Analysis of three years’ follow up shows mean reduction of different variables in groups A and B as dysmenorrhoea (visual analogue scale) 98.2±3.9% and 98.3±3.7% (p<0.0001) menstrual bleeding (blood-loss assessment chart) 92.2±11.2% and 85.0±17.5% (p<0.0001), chronic pelvic pain (pain-calendar) 98.8±2.7% and 96.4±4.9% (p<0.0001); uterine volume 27.8±9.0% and 28.7±9.6% (p<0.0005) maximum endo-myometrial junctional-zone thickness 30.2±7.9% and 26.0±4.8% (p<0.0005). Effects on groups A and B were comparable. Other observations were – amenorrhoea-27.5%, intermenstrual bleeding-37.3% and expulsion-6.9%. Conclusion: LNG-IUS is equally effective for long-term conservative management of both adenomyosis alone and with co-existent endometriosis. Key words: Adenomyosis; endometriosis; conservative treatment; LNG-IUS. DOI: http://dx.doi.org/10.4038/sljog.v32i2.3976 SLJOG 2010; 32(2): 27-33
Full text 1,582 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Objective: To study effects of levonorgestrel intra-uterine system (LNG-IUS) on adenomyosis with and without endometriosis. Design: Fifty-eight women with a confirmed diagnosis of adenomyosis after exclusion of confounding factors, and detection or exclusion of endometriosis were selected. They were categorized into group A (only adenomyosis, n=44) and group B (adenomyosis plus endometriosis, pre-treated by laparoscopic surgery, n=14) received LNG-IUS between July 2004 and January 2006 and were followed up on five different parameters.

Results

Analysis of three years’ follow up shows mean reduction of different variables in groups A and B as dysmenorrhoea (visual analogue scale) 98.2±3.9% and 98.3±3.7% (p<0.0001) menstrual bleeding (blood-loss assessment chart) 92.2±11.2% and 85.0±17.5% (p<0.0001), chronic pelvic pain (pain-calendar) 98.8±2.7% and 96.4±4.9% (p<0.0001); uterine volume 27.8±9.0% and 28.7±9.6% (p<0.0005) maximum endo-myometrial junctional-zone thickness 30.2±7.9% and 26.0±4.8% (p<0.0005). Effects on groups A and B were comparable. Other observations were – amenorrhoea-27.5%, intermenstrual bleeding-37.3% and expulsion-6.9%.

Conclusion

LNG-IUS is equally effective for long-term conservative management of both adenomyosis alone and with co-existent endometriosis. Key words: Adenomyosis; endometriosis; conservative treatment; LNG-IUS. DOI: http://dx.doi.org/10.4038/sljog.v32i2.3976 SLJOG 2010; 32(2): 27-33

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosischronic_pelvic_paindysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK